[1] Stamler J, Vaccaro O, Neaton JD, Wentworth D. For the Multiple Risk Factor Intervention Trail Research Group. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Invention Trial. Diabetes Care 1993;16:434-44.

[2] Kannel W. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985;110:1100-7.

[3] Jacoby RM, Nesto RW. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol 1992;20: 736-44.

[4] Mak KH, Moliterno DJ, Gragner CB, Miller DP, White HD, Wilcox RG, et al. For the GUSTO-I Investigators. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myo-cardial infarction. J Am Coll Cardiol 1997;30:171-9.

[5] Zuanetti G, Latini R, Maggione AP, Santoro L, Franzosi PG. For the GISSI-2 Investigators. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 1993;22:1788-94.

[6] Cruikshank N. Coronary thrombosis and myocardial infarction, with glycosuria. BMJ 1931;1:618-9.

[7] Sewdarsen M, Jialal I, Vythilingum SS, Govender G, Rajput MC. Stress hyperglycaemia is a predictor of abnormal glucose tolerance in Indian patients with acute myocardial infarction. Diabetes Res 1987;6: 47-9.

[8] Wahab NN, Cowden EA, Pearce NJ, Gardner MJ, Merry H, Cox JL. Is blood glucose an independent predictor ofmortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol 2002;40: 1748-54.

[9] Norhammar AM, Ryden L, Malmberg K. Independent risk factor for long-term prognosis after myo-cardial infarction even in nondiabetic patients. Diabetes Care 1999;22:1827-31.

[10] Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355:773-8.

[11] Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Circulation 1999;99:2626-32.

[12] Bellodi G, Manicardi V, Malavasi V, et al. Hyper-glycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol 1989;64:885-8.

[13] Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res 1997;34:248-53.

[14] Malmberg K, Ryden L, Efendic S, Herrllitz J, Nicol P, Waldenstrom A. A randomized trial-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction: effects on one year mortality. J Am Coll Cardiol 1995;26:57-65.

[15] Malmberg K, Ryden L, Hamsten A, Herlitz J, Nicol P, Waldenstrom A, et al. Effects of insulin treatment on cause specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J 1996;17:1337-44.

[16] Malmberg K. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997;34:187-220.

[17] Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutritional Examination Survey. JAMA 2002;287:356-9.

[18] Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-age men. JAMA 2002;288:2709-16.

[19] Norhammar A, Tenerz A, Nilsson G, Hansten A, Efendic S, Ryden L, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-4.

[20] Taubert G, Winkelmann BR, Schleiffer T, Marz W, Winkler R, Gok R, et al. Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J 2003;145:285-91.

[21] Kowalska I, Prokop J, Bachorzewska-Galewska H, Telejko B, Kinalskal I, Kochman W, et al. Disturbances of glucose metabolism in men referred for coronary arteriography. Diabetes Care 2001;24: 897-901.

[22] Lopaschuk GD, Stanley WC. Glucose metabolism in the ischemic heart. Circulation 1997;95:313-5.

[23] Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: part I. Circulation 2002;105:1727-33.

[24] Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation 1999;99z:578-88.

[25] Young LH, Renfu Y, Russell R, Hu X, Caplan M, Ren J, et al. Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo. Circulation 1997;95:415-22.

[26] Sun D, Nguyen N, DeGrado TR, Schwaiger M, Brosius FC III. Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane ofcardiac myocytes. Circulation 1994;89:793-8.

[27] Russell RR III, Yin R, Caplan MJ, Hu X, Ren J, Sholman GI, et al. Additive effects of hyperinsuline-mia and ischemia on myocardial GLUT1 and GLUT4 translocation in vivo. Circulation 1998;98: 2180-6.

[28] Sodi-Pallares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, et al. Effects of an intravenous infusion of a potassium-insulin-glucose solution on the electrocardiographic signs of myo-cardial infarction. A preliminary clinical report. Am J Cardiol 1962;9:166-81.

[29] Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152-6.

[30] Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan R, et al. On behalf of the ECLA Collaborative Group. Metabolic modulation of acute myocardial infarction. The ECLA glucose-insulin-potassium pilot trial. Circulation 1998;98: 2227-34.

[31] Stanley AW Jr, Moraski RE, Russell RO, Rogers WJ, Mantle JA, Kreisberg RA, et al. Effects of glucose-insulin-potassium on myocardial substrate availability and utilization in stable coronary artery disease. Studies on myocardial carbohydrate, lipid and oxygen arterial-coronary sinus differences in patients with coronary artery disease. Am J Car-diol 1975;36:929-37.

[32] Van der Horst ICC, Zijlstra F, van't Hof AW, Doggen CJ, de Boer MJ, Suryapranata H, et al. Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2003;42:784-91.

[33] Tune JD, Mallet RT, Downey HF. Insulin improves cardiac contractile function and oxygen efficiency during moderate ischemia without compromising myocardial energetics. J Mol Cell Cardiol 1998;30: 2025-35.

[34] Liao R, Jain M, Cui L, D'Agostino J, Aiello F, Luptak I, et al. Cardiac-specific over expression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 2002;106:2125-31.

[35] Jonasen AK, Brar BK, Mjos OD, Sack MN, Latchman DS, Yellon DM. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol 2000;32: 757-64.

[36] Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, et al. Nitric oxide mediates the antiapoptotic effect of in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endo-thelial nitric oxide synthase phosphorylation. Circulation 2002;105:1497-502.

[37] Jonassen AK, Aasum E, Riemersma RA, Mjos OD, Larsen TS. Glucose-insulin-potassium reduces in-farct size when administered during reperfusion. Cardiovasc Drugs Ther 2000;14:615-23.

[38] Yellon DM, Baxter GF. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distinct dream or near reality? Heart 2000; 83:381-7.

[39] Cleveland JC Jr, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulphonylurea hypo-glycaemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 1997;96:29-32.

[40] Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocar-dial infarction. J Am Coll Cardiol 1999;33: 119-24.

[41] Boord JB, Graber AL, Christman JWS, Powers AC. Practical management of diabetes in critically ill patients. Am J Respir Crit Care Med 2001;164: 1763-7.

[42] Van Den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.

[43] Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999;67:352-62.

[44] Lazar HL, Chipkin SR, Fitzgerald CA, Boa Y, Apstein C. Aggressive glucose management optimizes metabolism and reduces morbidity in diabetics coronary bypass patients. Circulation 2002;106: 1972.

[45] Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, et al. Optimal glycemic control is associated with lower rates of target vessel re-vascularization in diabetics undergoing elective percutaneous coronary intervention. JACC 2001; 66A:1223-36.

[46] Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668-73.

[47] Conti R. Partial fatty acid oxidation (pFOX) inhibition: a new therapy for chronic stable angina. Clin Cardiol 2003;26:161-2.

[48] Schofield RS, Hill JA. Role of metabolically active drugs in the management of ischemic heart disease. Am J Cardiovasc Drugs 2001;1:23-35.

[49] Schofield RS, Hill JA. The use of ranolazine in cardiovascular disease. Expert Opin Investig Drugs 2002;11(1):117-23.

[50] Yue T, Chen J, Boa W, Narayanan PK, Bril A, Jiang W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome pro-liferator-activated receptor-agonist rosiglitazone. Circulation 2001;104:2588-94.

[51] Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, et al. Pioglitazone, a peroxisome proliferator-activated receptor- agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106:3126-32.

[52] Zhu P, Lu L, Xu Y, Schwartz G. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 2000;101: 1165-71.

[53] Parulkar A, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134: 61-71.

[54] Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.

[55] Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients. A novel target of thiazolidine-diones. Circulation 2003;107:2664-9.

[56] DeDios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GL, Law RE, et al. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor- ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003; 107:2548-50.

[57] Choi SH, et al. Diabetes drug, rosiglitazone, reduces in-stent restenosis in diabetics, suggesting anti-inflammatory effects. Presented at the 63rd Session American Diabetes Association Scientific Sessions. June 13-17, 2003. New Orleans.

[58] Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshitama H. Potent inhibitory effect of troglita-zone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83(5):1818-20.

[59] Kirpichnikov D, McFarlane SI, Sowers JR. Metfor-min: an update. Ann Intern Med 2002;137:25-33.

[60] Mather KJ, Verma S, Anderson TJ. Improved endo-thelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001;37:1344-50.

[61] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with met-formin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854-65.

[62] Mak KH, Topol EJ. Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus. J Am Coll Cardiol 2000;35: 563-8.

[63] Poole-Wilson PA, Swedberg K, Cleland JGF, DiLenarda A, Hanrath P, Komajda M, Lubsen J, et al. Comparison of Carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.

[64] Mathew V, Holmes DR. Outcomes in diabetics undergoing revascularization. J Am Coll Cardiol 2002; 40:423-7.

[65] Libby P, Plutzky J. Diabetic macrovascular disease. The glucose paradox? Circulation 2002;106: 2760-3.


Cardiol Clin 23 (2005) 119-138


Supplements For Diabetics

Supplements For Diabetics

All you need is a proper diet of fresh fruits and vegetables and get plenty of exercise and you'll be fine. Ever heard those words from your doctor? If that's all heshe recommends then you're missing out an important ingredient for health that he's not telling you. Fact is that you can adhere to the strictest diet, watch everything you eat and get the exercise of amarathon runner and still come down with diabetic complications. Diet, exercise and standard drug treatments simply aren't enough to help keep your diabetes under control.

Get My Free Ebook

Post a comment